Research programme: protein therapeutics - Talecris Biotherapeutics
Latest Information Update: 04 Apr 2011
At a glance
- Originator Talecris Biotherapeutics
- Class Proteins
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 14 Apr 2005 Preclinical trials in Undefined indication in USA (parenteral)